G/MA/QR/N/GBR/1/Add.1  
24 février  2022 
(22-1804) Page: 1/7 
Comité de l'accès aux marchés  Original:  anglais  
 
  
NOTIFICATION PRÉSENTÉE CONFORMÉMENT À LA DÉCISION SUR LES  
PROCÉDURES DE NOTIFICATION DES RESTRICTIONS  
QUANTITATIVES (G/L/59/REV.1)  
ROYAUME -UNI 
Addendum  
La communication ci -après, datée du 2 4 février 2 022, est distribuée à la demande de la délégation 
du Royaume -Uni. 
 
A. Membre notifiant : Royaume -Uni 
B. Date de la notification : 17 février 2 022 
C. Première notification:  
 Oui 
 Non, dernière notification présentée dans le document (cote du document ): 
G/MA/QR/N/GBR/1  
D. Type de notification:  
 1. Complète (c 'est-à-dire notification de toutes les restrictions quantitatives en vigueur ) 
 2. Modifications apportées à une notification faite précédemment (cote du document)  qui 
sont de la nature suivante : 
  2.1 Introducti on de nouvelles restrictions, telles qu 'énumérées dans la section 1 . 
  2.2 Suppression de restrictions, tel qu 'indiqué plus bas dans la section G. 
  2.3 Modification d'une restriction notifiée précédemment, tel qu 'indiqué dans la 
section 1. 
 3. Notification inverse de restrictions maintenues par (Membre ): 
E. La notification contient des renseignements pour la période biennale (par 
exemple 2012 -2014) : 2020-2022 et concerne des restrictions en vigueur depuis le 
16 décembre 2021 
F. La présente notification contient les renseignements1 ci-après:  
 Section 1:  Liste des restrictions quantitatives actuellement en vigueur . 
 Section 2:  Renvoi à d 'autres notifications adressées à l 'OMC et contenant des 
renseignements sur des restrictions quantitatives actuellement  en vigueur, et 
renseignements additionnels . 
 
1 En anglais seulement.  G/MA/QR/N/GBR/1/Add.1  
- 2 - 
  G. Observations générales, y compris description de la suppression de restrictions 
notifiées au titre du point D.2.2 et date à laquelle elles ont cessé d 'être appliquées . 
1. Le présent  addendum modifie le document  G/MA/QR/N/GBR/1 en notifiant la restriction 
quantitative n° 1, qui met à jour et remplace la  restriction quantitative n° 21 , notifiée 
précédemment dans la section  1 du document  G/MA/QR/N/GBR/1 . Cette notification met 
à jour la liste des  codes de produits applicable s aux médicaments visés et fournit de plus 
amples renseignements sur la manière dont les mesures sont appliquées . 
2. Le Royaume -Uni notifie le retrait net de 76 médicaments de la liste des médicaments 
nécessaires au traitement des  patients du Royaume -Uni, à un moment où la COVID -19 
continue d 'avoir une incidence sur la demande et sur l 'offre des médicaments dont 
l'exportation est restreinte dans certaines circonstances limitées lorsqu 'ils sont déjà 
présents dans la chaîne d 'approvi sionnement du pays et sont destinés à ses patients.  
3. Ce sont des mesures temporaires, instaurées pour prévenir une grave pénurie de 
médicaments nécessaires à la protection de la santé des personnes. Ces mesures sont 
réexaminées régulièrement et ne sont appl iquées que lorsqu 'il ne peut être satisfait aux 
besoins essentiels par d 'autres mesures. Le 3 août 2021, 30 médicaments ont été retirés 
de la liste. Au 16 décembre 2021, 47 autres médicaments avaient été retirés de la liste. 
Un médicament a été ajouté à la  liste. 
4. La notification G/MA/QR/N/GBR/1  du Royaume -Uni comprenait des détails concernant 
l'Irlande du Nord. La présente notification ne modifie pas ces dispositions, qui continuent 
de s'appliquer.  
   
  G/MA/QR/N/GBR/1/Add.1  
- 3 - 
 
Section 1 : List of quantitative restrictions that are currently in force  
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
1 Measures to 
regulate exports of 
certain 
medicaments.  CP-X Medicines fall 
under the 
following 
commodity 
codes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3002.15.00.00  
 1. Heading 3002 - 
Classification  
Human blood; animal 
blood prepared for 
therapeutic, prophylactic 
or diagnostic uses; 
antisera, other blood 
fractions and 
immunological products, 
whether or not modified 
or obtained by means of 
biotechnological 
processes; vacci nes, 
toxins, cultures of micro -
organisms (excluding 
yeasts) and similar 
products; cell cultures, 
whether or not modified  
 
 
 
Product Description per 
Commodity Code under 
Heading 3002  
Immunological products, 
put up in measured 
doses or in forms or 
packings for retail sale  
 
 Article XX(b) GATT  
Protection of human, 
animal or plant life or 
health.  
 Regulation 43(2) of 
the Human Medicines 
Regulations 2012 
requiring wholesale 
dealers to ensure 
continued supply of 
medicinal products so 
that the needs of 
patients in the UK are 
met. Further details 
can be found through: 
https://www.legislatio
n.gov.uk/uksi/2012/1
916/contents/made  
 
The date restrictions 
came into effect varies 
by me dicine; this is 
specified for each 
medicine on the list, 
updated on 16 
December 2021 and 
available  on gov.uk at  
 
https://assets.publishi
ng.service.gov.uk/gov
ernment/uploads/syst
em/uploads/attachme
nt_data/file/1042790/
restricted -medicines -The list of medicines 
is maintained by the 
Department of Health 
and Social Care.  
 
These measures are 
reviewed regularly.  
A full change log of 
previous measures, 
from October 2019, 
can be found here:  
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk  
 
Medicines included 
on this list me et the 
following conditions:  
• the medicine is 
required to 
meet the needs 
of UK patients  
• the medicine is 
either being 
exported or is 
at threat of 
being exported    
  G/MA/QR/N/GBR/1/Add.1  
- 4 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
list-december -2021-
v3.csv/preview   
 
 
    
 
 
 
 
 
 
 
 
 
 
 2. Heading 3004 - 
Classification  
Medicaments consisting 
of mixed or unmixed 
products for therapeutic 
or prophylactic uses, put 
up in measured doses 
(including those in the 
form of transdermal 
administration systems) 
or in forms or packings 
for retail sale    • the export of 
the medicine is 
either 
contributing to, 
or may 
contribute to, a 
shortage of 
that medicine 
in the UK.  
 
Medicines on this list 
which have been 
produced to fulfil 
contracts overseas 
are not subject to  
    
 
 
3004.20.00  
 
3004.31.00  
3004.32.00  
 
 
 
3004.39.00  
3004.49.00  
 
 Product Description per 
Commodity Code under 
Heading 3004  
Other, containing 
antibiotics  
Containing insulin  
Containing corticosteroid 
hormones, their 
derivatives or structural 
analogues  
Other  
Other  
   restriction. As such, 
restrictions only 
apply to wholesaler 
dealer license holde rs 
that are not the 
market authorisation 
holder for a medicine 
intended for export. 
The measures are 
designed to ensure 
wholesalers fulfil 
their legal obligations 
to maintain supply to 
UK patients.    
  G/MA/QR/N/GBR/1/Add.1  
- 5 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       These restrictions are 
only applied and 
maintained where  
    Further detail of these 
medicines can be found 
at  
https://www.gov.uk/gov
ernment/publications/m
edicines -that-cannot -be-
parallel -exported -from-
the-uk 
 
These restrictions apply 
in certain circumstances 
to exports of specified 
medicines which are 
placed on the UK market 
for UK patients and 
needed to protect human 
health, including to treat 
Covid -19, inter alia.  
 
   alternative measures 
are not considered 
sufficient on their 
own to ensure tha t 
UK supply meets 
demand.  
A number of 
exemptions apply to 
medicines in scope of 
these restrictions. 
For example, exports 
destined for 
international 
humanitarian 
organisations such as 
COVAX are not 
covered. A full list of 
exemptions can be 
found  at 
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk 
 
Requests for 
exemptions are 
considered on a case -   
  G/MA/QR/N/GBR/1/Add.1  
- 6 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       by-case basis. These 
can be submitted by 
a foreign government  
or government 
agency, or a 
wholesaler on their 
behalf at 
restrictedmedicines
@dhsc.gov.uk    
 
Further information 
on these measures is 
available here:  
https://www.gov.uk/
guidance/parallel -
export -and-
hoarding -of-
restricted -medicines  
  
It is the responsibility 
of the wholesaler to 
ensure any exports 
are made or withheld 
in compliance with 
these restrictions. 
Failure to comply 
with these 
restrictions may lead 
to regulatory action 
by the Medicines and 
Healthcare products 
Regulatory Authori ty 
(MHRA) against the    
  G/MA/QR/N/GBR/1/Add.1  
- 7 - 
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
 
       wholesale dealer 's 
licence.  
There are no 
additional steps or 
declarations required 
from a customs 
perspective.  
 
__________